Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Multiple Myeloma Testing and Personalized Treatment

Multiple Myeloma Testing and Personalized Treatment

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Drs. William Bensinger and Dr. Noopur Raje discuss testing for the treatment of myeloma with Andrew Schorr from Patient Power. With the heterogeneity of the disease, adjusting the drug schedule and combination for the individual patient is the key to treatment efficacy and the control of side effects. Dr. Raje describes the panel of tests used to determine the appropriate individualized treatment regimen.

Related Videos

Limiting Myeloma Treatment Side Effects

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Drs. William Bensinger and Noopur Raje discuss ways to limit the side effects of treatment for myeloma with Andrew Schorr from Patient Power. Dr. Raje states that the goal is not just to live longer, but to live longer well. Because every patient experiences different side effects from the treatment of the disease, Dr. Raje says the key is communication with your medical team, including nurses. Listen for more tips on managing side effects of myeloma treatment.

Multiple Myeloma Treatment and Research

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Drs. William Bensinger of Seattle Cancer Care Alliance, and Noopur Raje of Massachusetts General Hospital discuss treatment and research for multiple myeloma with Andrew Schorr from Patient Power. Dr. Raje, who researches drugs that can help with the bone complications of myeloma, states that they are able to decrease the risk of fractures by about 50% with bisphosphonates. She also discusses a clinical trial which uses osteoblasts to promote bone healing. In the more than 20 years that Dr. Bensinger has studied myeloma, he has never been more hopeful about his ability to fight the disease. Proteasome inhibitors such as bortezomib have dramatically changed the landscape. Remissions have lasted longer and patients have lived longer as a result of these drugs. Learn more about advancements in treatment of myeloma.

Understanding a Multiple Myeloma Diagnosis

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Drs. William Bensinger and Dr. Noopur Raje discuss understanding the diagnosis of multiple myeloma with Andrew Schorr from Patient Power. Dr. Bensinger explains MGUS (monoclonal gammopathy of undetermined significance) and tells about the risk of progression to active myeloma, which is about 1% a year. He also discusses smoldering multiple myeloma, or asymptomatic myeloma. People with this form of the disease have a higher percentage of plasma cells in their blood and bone marrow, and a higher level of M protein in their blood, but they do not have bone disease, kidney disease and are not anemic. Learn more about their risk of progression to active myeloma.